MK-1406

Unknown / undisclosed

Also known as CD388

Phase 2Mechanism not established
Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Other / comorbidity
NCT07159763 · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2025-09-25 – 2027-07-02 · Influenza
What this study did
Phase 2 (3)
Other / comorbidity
NCT07225959 · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2025-10-29 – 2027-07-31 · Healthy Participants
What this study did
NCT06609460 · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2024-09-20 – 2025-10-09 · Influenza
What this study did
NCT05523089 · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2022-09-09 – 2023-07-17 · Influenza
What this study did
Phase 1 (4)
Other / comorbidity
NCT07743151 · Merck Sharp & Dohme LLC
2026-09-10 – 2027-02-05 · Healthy
What this study did
NCT07300085 · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2025-11-08 – 2026-12-31 · Healthy Participants
What this study did
NCT05285137 · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2022-03-14 – 2023-10-27 · Healthy
What this study did
NCT05619536 · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2022-10-18 – 2023-07-14 · Healthy
What this study did

Competitive landscape

This drug's own stage for Seasonal Influenza: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
MK-1406: this drugStage not on recordUndisclosed—not yet gradedNo reviewed efficacy summary in this indication
GSK4382276
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
GSK5475152
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
PF-07252220
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
PF-07845104
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
PF-07926307
—(overall)
Combination—not yet gradedNo reviewed efficacy summary in this indication
SP0287
—(overall)
Combination—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow MK-1406 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Healthy ParticipantsRecruiting
Est. primary completion 2026-12-31 · NCT07300085 · CT.gov ↗
What to watch
2027 (3)
February 2027 (1)
Phase 1HealthyRecruiting
Est. primary completion 2027-02-05 · NCT07743151 · CT.gov ↗
What to watch
July 2027 (2)
Phase 3InfluenzaRecruiting
Est. primary completion 2027-07-02 · NCT07159763 · CT.gov ↗
What to watch
Phase 2Healthy ParticipantsActive not recruiting
Est. primary completion 2027-07-31 · NCT07225959 · CT.gov ↗
What to watch

See the full readout calendar ↗